Simcere Pharmaceutical

• NCT01529164

  Collaborator, Phase 2, Status unknown, 51 people, 8 Feb 2012

• Roche

  Licence, 1 Sept 2026

• Acquisition

  25 Mar 2026

• Boehringer Ingelheim

  Licence, 27 Jan 2026

• Ipsen

  Licence, 22 Dec 2025

• Licence

  Vigonvita, 3 Dec 2025

• Financing

  2 Sept 2025

• Acquisition

  26 Aug 2025

• NextCure

  Licence, 16 Jun 2025

• AbbVie

  Licence, 13 Jan 2025

• Collaboration

  Targetrx, 2 Sept 2024

• Acquisition

  1 Jan 2024

• Licence

  Connect Biopharma, 21 Nov 2023

• Collaboration

  Andicon, 10 Oct 2023

• Collaboration

  Mabpharm, 20 Aug 2023

• Idorsia

  Licence, 16 Nov 2022

• Almirall

  Licence, 29 Sept 2022

• Collaboration

  Avilex, 15 Dec 2021

• Licence

  29 Jun 2021

• IPO filing

  13 Oct 2020

Sources: www1.hkexnews.hk